Impact of NIH Funding Cuts on Drug Development

Last week, the Congressional Budget Office (CBO) released a report titled “How Changes to Funding for the NIH and Changes in the FDA’s Review Times Would Affect the Development of New Drugs.” The report evaluates two scenarios: A permanent 10 percent reduction in the amount of funding that the government provides to the NIH, andA…

Read More

AI-Powered Insights for Personalized Customer Experiences: The Art of Data-Driven Engagement

While advanced analytics and AI can unlock unprecedented insights, it’s the thoughtful application of these insights that transforms routine interactions between pharmaceutical representatives and healthcare providers into lasting relationships. The post AI-Powered Insights for Personalized Customer Experiences: The Art of Data-Driven Engagement appeared first on MedCity News.

Read More

La Casa Blanca llama “desperdicio” a fondo para emergencias creado luego del 9/11. Estados republicanos y demócratas dicen que es esencial

SACRAMENTO, California. — La iniciativa del presidente Donald Trump de eliminar un programa federal de preparación ante situaciones de desastre ha generado preocupación entre funcionarios de salud estatales, tanto en Texas —gobernado por republicanos— como en California, bastión demócrata. El Programa de Preparación Hospitalaria (HPP) fue creado hace más de dos décadas tras los ataques…

Read More

Preventing Medical Errors in Patient Identity Through Data Matching, VBC, and Interoperability Standards

[Sponsored] A webinar, sponsored by Verato, offered a robust discussion with executives from Providence, Yale New Haven Health System and Verato on navigating an increasingly complex landscape of sharing electronic patient data. The post Preventing Medical Errors in Patient Identity Through Data Matching, VBC, and Interoperability Standards appeared first on MedCity News.

Read More

Fatal Complication of Stem Cell Transplants Gets Its First FDA-Approved Therapy

Omeros’s complement system drug Yartemlea is now FDA approved for treating a severe and potentially fatal complication of hematopoietic stem cell transplants. Our recap of other regulatory actions includes drug approvals in cancer, rare disease, and metabolic disorders. The post Fatal Complication of Stem Cell Transplants Gets Its First FDA-Approved Therapy appeared first on MedCity…

Read More